Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.57 |
| ▸ | MME | P08473 | 6/20 | 0.57 |
| ▸ | CPA1 | P15085 | 6/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.57 |
| ▸ | CTSD | P07339 | 5/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052882 | 0.94 | CTSD (0.58) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL30051990 | 0.94 | CTSD (0.61) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL29437876 | 0.93 | ACE (0.55) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL29876711 | 0.91 | ACE (0.58) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL30051600 | 0.91 | ACE (0.68) | ACEMMECPA1ACE2 | |
| SCHEMBL29378009 | 0.91 | CTSD (0.58) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL30051481 | 0.90 | ACE (0.64) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL30592752 | 0.90 | ACE (0.64) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL30051904 | 0.90 | MME (0.57) | ACEMMECPA1ACE2CTSD | |
| SCHEMBL31514336 | 0.90 | BACE1 (0.51) | ACEMMECPA1ACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1636 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| CN-114080232-B | Extracellular vesicles for vaccine delivery | Lhasa Sales Co.,Ltd. (CH) | 2026-05-26 | — | — | CN | disclosed |
| CN-114761428-B | Anti-hemagglutinin antibodies and methods of use thereof | 瑞泽恩制药公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-106794263-B | Vaccine with antigen and interleukin-21 as adjuvant | 宾夕法尼亚大学理事会 | 2026-05-19 | — | — | CN | disclosed |
| CN-115135669-B | Modified Fc region | 硕腾服务有限责任公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-116355100-B | Base editor and construction method and application thereof | 复旦大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132191-A1 | METHODS FOR MODULATING ACTIVITY OF IL-18 FOR TREATMENT OF CD4+ T CELL MEDIATED AUTOIMMUNITY AND IMMUNOPATHOLOGY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4729542-A1 | ANTIGEN-BINDING POLYPEPTIDES AGAINST CD229 | Universitätsklinikum Hamburg-Eppendorf (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4709427-A1 | METHOD FOR DETECTING A GD2 POSITIVE CANCER | Prinses Máxima Centrum voor Kinderoncologie B.V. (NL) | 2026-03-18 | — | — | EP | disclosed |
| CN-108350412-B | Method for producing aldehyde | 味之素株式会社 | 2022-02-11 | — | — | CN | disclosed |
| CN-108676803-B | Plant medicago truncatula floral organ stigma exsertion gene and encoded protein and application thereof | 中国农业科学院生物技术研究所 | 2022-02-08 | — | — | CN | disclosed |
| CN-114008197-A | Metabolic engineering for simultaneous consumption of xylose and glucose to produce chemicals from second generation sugars | 布拉斯科公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008069-A | Compositions of exosomes and AAV | 科迪亚克生物科学公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-111394410-B | High-catalytic-activity neuraminic acid synthase and application thereof | 江南大学 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993989-A | Process for producing ergothioneine | 丹麦科技大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-111856024-B | Method for detecting interaction between biological membrane proteins and kit used in method | 清华大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-113993534-A | Protein conjugates against iRhom2 | 特殊外科医院 | 2022-01-28 | — | — | CN | disclosed |
| CN-113993552-A | Adeno-associated virus vector formulations and methods | 再生生物股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-110066810-B | Tamarix chinensis plasma membrane Na+/H+Antiporter gene and application thereof | 南京农业大学 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885MME 824/4885CPA1 245/4885 |
| US-20260132191-A1 | METHODS FOR MODULATING ACTIVITY OF IL-18 FOR TREATMENT OF CD4+ T CELL MEDIATED AUTOIMMUNITY AND IMMUNOPATHOLOGY | IL18, CD4, IL2 | ACE 2533/4885MME 4118/4885CPA1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.